ROGER M. PERLMUTTER - 04 Feb 2026 Form 3 Insider Report for Eikon Therapeutics, Inc. (EIKN)

Role
Chief Executive Officer and Director Exhibit List - Exhibit 24 - Power of Attorney, Director
Signature
/s/ Benjamin Thorner, Attorney-in-Fact
Issuer symbol
EIKN
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
3
Filing time
04 Feb 2026, 21:21:16 UTC
Previous filing
08 Apr 2024
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PERLMUTTER ROGER M Chief Executive Officer and Director Exhibit List - Exhibit 24 - Power of Attorney, Director C/O EIKON THERAPEUTICS, INC., 230 HARRIET TUBMAN WAY, MILLBRAE /s/ Benjamin Thorner, Attorney-in-Fact 04 Feb 2026 0001184228

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EIKN Common Stock 1,190,999 04 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EIKN Series A-1 Preferred Stock 04 Feb 2026 Common Stock 170,143 See footnote F1, F2
holding EIKN Series D Preferred Stock 04 Feb 2026 Common Stock 114,714 See footnote F2, F3
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 869,981 $9.85 Direct F4
holding EIKN Stock Option (Right to Buy) 04 Feb 2026 Common Stock 1,608,481 $9.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series A-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2 The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person has the sole pecuniary interest in the securities.
F3 The Series D Preferred Stock is convertible into Common Stock on a 1-for 7.4578 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series D Preferred Stock will be converted into shares of Common Stock of the Issuer.
F4 The shares underlying the option will vest in equal monthly installments for four years after the vesting starting date, subject to the Reporting Person's continued service through each date.

Remarks:

Chief Executive Officer and Director Exhibit List - Exhibit 24 - Power of Attorney